Psychologists in Pepper Pike, OH Accepting Medicare
3 Psychologists found. Showing 1 - 3
 Dr. Sally L. Wilson, PH.D. Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 30500 Fairmount Blvd Ste 9, Pepper Pike, OH 44124 Phone: 440-442-9355 |
Dr. Jennifer Catherine Corlett, PH.D. Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 2600 Lander Rd, Pepper Pike, OH 44124 Phone: 440-442-4160 |
Carol D Smith, PHD Psychologist - Clinical Child & Adolescent Medicare: Not Enrolled in Medicare Practice Location: 3737 Lander Rd, Pepper Pike, OH 44124 Phone: 216-831-2255 Fax: 216-378-3906 |
News Archive
Synthetic compound targets enzyme that supports survival and dissemination of metastatic cells
Cancer can most often be successfully treated when confined to one organ. But a greater challenge lies in treating cancer that has metastasized, or spread, from the primary tumor throughout the patient's body.
Breathing heavy wildfire smoke may increase risk of out-of-hospital cardiac arrest
Exposure to heavy smoke during recent California wildfires raised the risk of out-of-hospital cardiac arrests up to 70%.
Magstim Rapid2 Therapy System receives FDA clearance for treatment of drug resistant MDD
The Magstim Company Ltd, an innovative and award winning Wales-based medical device manufacturer, has received FDA 510(k) clearance to market its Magstim Rapid2 Therapy System for the treatment of drug resistant Major Depressive Disorder (MDD) in the United States. The clearance enables Magstim to significantly increase access to cutting-edge Repetitive Transcranial Magnetic Stimulation (rTMS) technology for patients and clinicians.
Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments
Clinical Data, Inc., and Santen Pharmaceutical Co., Ltd., today announced that Santen has exercised its option to license Clinical Data's highly selective adenosine A2A agonist compound, ATL313, for the development of topical treatments for certain ophthalmic diseases, including glaucoma. ATL313, a promising late-stage preclinical compound, has shown significant pharmacological effects in vivo and has been nominated as a clinical candidate.
› Verified 2 days ago